ReviewNeurodegenerative disease management2015
Mild cognitive impairment: an update in Parkinson's disease and lessons learned from Alzheimer's disease.
Review in Neurodegenerative disease management, 2015. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 19 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
19 citing papers in PubMed, 1 synthesis or guideline pooled it, 38 citations in OpenAlex.
- No genetic association between attention-deficit/hyperactivity disorder (ADHD) and Parkinson's disease in nine ADHD candidate SNPs.Attention deficit and hyperactivity disorders · 2017Pooled it
- Language impairment as a risk factor for dementia conversion in parkinson's disease with mild cognitive impairment: a quantitative EEG study.Journal of neural transmission (Vienna, Austria : 1996) · 2026Article
- Emerging Role of Mesenchymal Stromal Cell and Exosome Therapies in Treating Cognitive Impairment.Pharmaceutics · 2025Review
- Neurocognitive Impairment and Social Cognition in Parkinson's Disease Patients.Neurology international · 2024Review
- Pathogenesis of PMEpigenomes · 2024Review
- Mild cognitive impairment and microbiota: what is known and future perspectives.Frontiers in medicine · 2024Review
- Screening for Cognitive Impairment in Movement Disorders: Comparison of the Montreal Cognitive Assessment and Quick Mild Cognitive Impairment Screen in Parkinson's Disease and Lewy Body Dementia.Journal of Alzheimer's disease reports · 2024Article
- REM Sleep Behavior Disorder and Cognitive Functions in Parkinson's Patients: A Systematic Review.Journal of clinical medicine · 2023Review
- CSF neurochemical profile and cognitive changes in Parkinson's disease with mild cognitive impairment.NPJ Parkinson's disease · 2023Article
- Is the Random Forest Algorithm Suitable for Predicting Parkinson's Disease with Mild Cognitive Impairment out of Parkinson's Disease with Normal Cognition?International journal of environmental research and public health · 2020Article
- Enhancement of Executive Functions but Not Memory by Multidomain Group Cognitive Training in Patients with Parkinson's Disease and Mild Cognitive Impairment: A Multicenter Randomized Controlled Trial.Parkinson's disease · 2020Article
- The interactions of dopamine and oxidative damage in the striatum of patients with neurodegenerative diseases.Journal of neurochemistry · 2020Article
- Pain Severity and Interference in Different Parkinson's Disease Cognitive Phenotypes.Journal of pain research · 2020Article
- Insulin Resistance Is a Risk Factor for Mild Cognitive Impairment in Elderly Adults with T2DM.Open life sciences · 2019Article
- Evolution of diagnostic criteria and assessments for Parkinson's disease mild cognitive impairment.Movement disorders : official journal of the Movement Disorder Society · 2018Review
- Article
- Parkinson's Disease: Cognitive Impairment.Focus (American Psychiatric Publishing) · 2017Review
- Odor selectivity of hyposmia and cognitive impairment in patients with Parkinson's disease.Clinical interventions in aging · 2017Article
- Fragile X-associated tremor/ataxia syndrome: phenotypic comparisons with other movement disorders.The Clinical neuropsychologist · 2016Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors at 1 institution in 1 country.
Funding
Abstract
Cognitive dysfunction is an important focus of research in Parkinson's disease (PD) and Alzheimer's disease (AD). While the concept of amnestic mild cognitive impairment (MCI) as a prodrome to AD has been recognized for many years, the construct of MCI in PD is a relative newcomer with recent development of diagnostic criteria, biomarker research programs and treatment trials. Controversies and challenges, however, regarding PD-MCI's definition, application, heterogeneity and different trajectories have arisen. This review will highlight current research advances and challenges in PD-MCI. Furthermore, lessons from the AD field, which has witnessed an evolution in MCI/AD definitions, relevant advances in biomarker research and development of disease-modifying and targeted therapeutic trials will be discussed.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.